Women are more likely to suffer seizures during menstrual cycles when ovulation doesn?t occur and progesterone therefore doesn?t increase, according to a study published online July 14 in Epilepsia.
Women are more likely to suffer seizures during menstrual cycles when ovulation doesn’t occur and progesterone therefore doesn’t increase, according to a study that was published online July 14 in Epilepsia.
To investigate whether lack of increase in progesterone during anovulatory cycles is linked to an increase in seizures, the study examined data on 92 women who had both anovulatory and ovulatory menstrual cycles during the 3-month baseline phase of a multicenter trial of progesterone therapy for intractable focal onset seizures. Ovulatory cycles were defined by midluteal progesterone levels of 5 ng/mL or greater. Average daily seizure frequency was 29.5% greater during anovulatory cycles than ovulatory cycles for secondary generalized tonic-clonic seizures (2°GTCS) but didn’t differ for simple or complex partial seizures or all seizures combined. The researchers found a significant correlation between proportional increases in 2°GTCS during anovulatory cycles and proportional increases in estradiol-progesterone serum level ratios.
“These findings support a possible role for reproductive steroids in 2°GTCS occurrence,” they conclude, adding, “if hormones play a role in seizure occurrence, there may also be a role for hormones in seizure therapy.”
The researchers observe that “the finding of an association between increased 2°GTCS frequency and anovulatory cycles and the existence of a greater frequency of anovulatory cycles among women with epilepsy suggest that greater attention be devoted to the ovulatory status of women with epilepsy, not only with regard to general reproductive health and fertility but also for comprehensive seizure management.”
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More